Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Q2 FY26 Earnings Results:
-
Revenue from Operations: ₹3,302 crore, up 14% YoY from ₹2,889 crore
-
EBITDA: ₹1,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from 32.5% in Q2 FY25)
-
Net Profit (PAT): ₹591 crore, up 30.5% YoY from ₹453 crore
-
EPS: ₹17.46, up 30% YoY
-
PAT margin improved to 17.9% (from 15.7% in Q2 FY25)
-
India business revenue: ₹1,820 crore, up 12% YoY; chronic therapies (Cardiac +14%, Gastro +15%, Derma +29%) outpaced Indian Pharma Market (IPM) growth
-
Brazil revenue: ₹318 crore, up 21% YoY; US revenue: ₹337 crore, up 26% YoY (driven by new launches and volume gains); Germany business down 5% YoY (currency-adjusted) due to supply disruptions
-
Branded markets contributed 73% of sales
-
Strong operating cash flow and balance sheet
-
Company received regulatory approvals for JB Chemicals acquisition (expected closure: Jan 2026)
Management Commentary & Strategic Insights
-
Management highlighted outperformance in chronic and specialty portfolios in India, with new launches and PCPM gains
-
Branded markets (India, Brazil) and the US segment were called out as key value drivers, backed by market share gains and a mix of price, volume, and new launches
-
Germany expected to recover from supply headwinds by Q4 FY26
-
Focus remains on organic and inorganic growth; the JB Chemicals acquisition expected to expand branded portfolio and synergies
-
Ongoing investment in field force (adding 600 MRs in FY26E) and entry into new therapeutic areas forecast strong medium-term growth
-
Company reiterates guidance for sustained growth in India, US, Brazil, and margin-leveraging on volume and synergy realization post-acquisition
Q1 FY26 Earnings Results
-
Revenue from Operations: ₹3,177 crore, up 11.5% YoY
-
PAT: ₹548 crore, up 24% YoY
-
EBITDA: ₹1,033 crore, 32.5% margin
-
India business grew 12% YoY; US and Brazil growth continued
-
Margins remained healthy, with disciplined cost and product mix management
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,